Timothy Patton
Specialist
3601 5th Ave, Suite 5a Falk Medical Building
Pittsburgh, PA 15213
- Medicare participating
At a glance
- Medical school
- Lake Erie College of Osteopathic Medicine, Erie (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 316
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: Lake Erie College of Osteopathic Medicine, Erie
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Specialist primary
PA license OS012408
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
Medical groups
- University of Pittsburgh Physicians (4,236 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 316
- Services billed
- 815
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 206 | 181 |
| Established patient office or other outpatient visit, 30-39 minutes | 144 | 114 |
| Destruction of precancer skin growth, 2-14 growths | 99 | 27 |
| Destruction of precancer skin growth, 1 growth | 72 | 59 |
| Destruction of skin growth, 1-14 growths | 51 | 44 |
| Biopsy of related skin growth, first growth | 47 | 41 |
| New patient office or other outpatient visit, 30-44 minutes | 29 | 29 |
| New patient office or other outpatient visit, 45-59 minutes | 29 | 29 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 85 payments worth $67,374 in total to this clinician.
| Genzyme Corporation | $33,205 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $33,120 |
| Galderma Laboratories, L.P. | $242 |
| Journey Medical Corporation | $227 |
| AbbVie Inc. | $205 |
| Arcutis Biotherapeutics, Inc. | $106 |
| E.r. Squibb & Sons, L.l.c. | $50.57 |
| Janssen Biotech, Inc. | $50.34 |
| Compensation for services other than consulting (speaking, faculty) | $34,124 |
|---|---|
| Consulting Fee | $28,255 |
| Travel and Lodging | $2,698 |
| Food and Beverage | $2,297 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 17, 2025 | Consulting Fee | $15,545 |
| Regeneron Healthcare Solutions, Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $8,350 |
| Genzyme Corporation Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $8,016 |
| Regeneron Healthcare Solutions, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,678 |
| Regeneron Healthcare Solutions, Inc. Jul 25, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,676 |
| Genzyme Corporation Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $4,342 |
| Regeneron Healthcare Solutions, Inc. Jul 25, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,008 |
| Genzyme Corporation Oct 30, 2025 | Consulting Fee DUPIXENT · Immunology | $3,615 |
| Regeneron Healthcare Solutions, Inc. Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,839 |
| Regeneron Healthcare Solutions, Inc. Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
All 28 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| Regeneron Healthcare Solutions, Inc. Oct 31, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,670 |
| Genzyme Corporation Oct 30, 2025 | Consulting Fee DUPIXENT · Immunology | $3,615 |
| Genzyme Corporation Oct 28, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $8,016 |
| Genzyme Corporation Oct 28, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Chapel Hill, NC · in-kind | $330 |
| Genzyme Corporation Oct 28, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Chapel Hill, NC · in-kind | $271 |
| Genzyme Corporation Oct 28, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Chapel Hill, NC | $113 |
| Genzyme Corporation Oct 28, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Chapel Hill, NC | $40.00 |
| Genzyme Corporation Oct 17, 2025 | Consulting Fee | $15,545 |
| Genzyme Corporation Oct 17, 2025 | Consulting Fee | $411 |
| Regeneron Healthcare Solutions, Inc. Oct 17, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to NEW WILMINGTON, PA · in-kind | $87.78 |
| Genzyme Corporation Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $4,342 |
| Regeneron Healthcare Solutions, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $5,678 |
| Regeneron Healthcare Solutions, Inc. Jul 25, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,676 |
| Regeneron Healthcare Solutions, Inc. Jul 25, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $4,008 |
| Regeneron Healthcare Solutions, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,169 |
| Regeneron Healthcare Solutions, Inc. Jun 27, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,839 |
| Regeneron Healthcare Solutions, Inc. Apr 29, 2025 | Travel and Lodging travel to LATHAM, NY · in-kind | $43.92 |
| Regeneron Healthcare Solutions, Inc. Apr 29, 2025 | Travel and Lodging travel to LATHAM, NY · in-kind | $31.36 |
| Regeneron Healthcare Solutions, Inc. Apr 29, 2025 | Travel and Lodging travel to LATHAM, NY · in-kind | $20.00 |
| Regeneron Healthcare Solutions, Inc. Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $8,350 |
| Regeneron Healthcare Solutions, Inc. Apr 17, 2025 | Travel and Lodging travel to LATHAM, NY · in-kind | $180 |
| Regeneron Healthcare Solutions, Inc. Apr 1, 2025 | Travel and Lodging travel to LATHAM, NY · in-kind | $452 |
| Regeneron Healthcare Solutions, Inc. Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) | $390 |
| Regeneron Healthcare Solutions, Inc. Mar 24, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CORAL GABLES, FL · in-kind | $428 |
| Regeneron Healthcare Solutions, Inc. Mar 24, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CORAL GABLES, FL · in-kind | $173 |
| Regeneron Healthcare Solutions, Inc. Mar 17, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CORAL GABLES, FL · in-kind | $492 |
| Regeneron Healthcare Solutions, Inc. Mar 17, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to CORAL GABLES, FL · in-kind | $35.25 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $19,872 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06003426 - A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis
E.r. Squibb & Sons, L.l.c. - Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
E.r. Squibb & Sons, L.l.c. · Completed · NCT04036435 - Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
E.r. Squibb & Sons, L.l.c. · Completed · NCT05478499 - A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Argenx US, Inc. - A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Regeneron Pharmaceuticals, Inc. · Completed · NCT04206553
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.